EMAS Pharma has rebranded as Evestia Clinical as it sets its sights on rapid growth as a provider of clinical research in oncology and rare diseases globally. Evestia Clinical is backed by Kester Capital and headed by Richard Barfield (Chairman), Lewis Cameron (CEO), Roy Ovel (CCO), and Carl Hvass (CFO). The name Evestia is inspired by the company’s mission to pioneer transformational advancements in clinical research. It represents a commitment to making a lasting imprint in the industry by ...